|
Aggregate Total Award of $20.4 Million for Clinical Development of HIV/AIDS Vaccine
ATLANTA, Sept. 1, 2011 - GeoVax Labs, Inc.(OTCBB:GOVX), an
Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV)
infections, today announced the increase of an existing $3.6 million annual award to $4.4 million for its
Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) Grant supporting GeoVax's HIV/AIDS
vaccine program.
This five-year grant was originally awarded in 2007 to GeoVax by the National Institutes of Health-National
Institute of Allergy & Infectious Disease (NIH-NIAID), an agency of the U.S. government. The increase reflects an
administrative supplement to support vaccine response characterization. Only highly successful IPCAVD grants
receive supplements, which allow these successful programs to move more rapidly. This most recent
supplement for the 2011-12 grant year is the third for the GeoVax program, bringing the initial
award of $15.4 million now to an aggregate award of $20.4 million.
Harriet Robinson, Ph.D., GeoVax's Chief Scientific Officer, stated, "This award is important for the advancement of
our GM-CSF adjuvanted vaccine that is achieving unprecedented levels of prevention of infection. When we started this
project, I thought we could only control, not prevent, infections. It is truly wonderful to be achieving high levels
of prevention of infection, and we are working very hard to move the vaccine through the needed efficacy trials for
human use."
About GeoVax
GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV. Our goals include developing
HIV/AIDS vaccines for global markets, overseeing the manufacture and testing of these vaccines under GMP/GLP
conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining
regulatory approvals to move the product forward. GeoVax's vaccines are unique in expressing virus like
particles that display the trimeric membrane bound form of the HIV-1 envelope glycoprotein. All
preventative Phase 1 human clinical trials conducted to date tested various combinations and
doses of our DNA and MVA vaccines, their ability to raise anti-HIV humoral (antibody) and
cellular (cytotoxic T cell) immune responses, as well as, the vaccines' safety.
Successful results from Phase 1 testing supported the initiation of the first
Phase 2 testing. GeoVax's Phase 2 human trial began in January 2009 and
involves 300 participants at sites in the United States and South
America. Recently GeoVax began enrolling patients in a Phase
1 therapeutic trial for individuals already infected with HIV.
For more information, please visit www.geovax.com.
Forward-Looking Statements
Certain statements in this document are "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act. These statements are based on management's current expectations and are
subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in
these statements due to a variety of factors, including whether: GeoVax can develop and manufacture these
vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use,
GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary
to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is
development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax
will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which
GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not
intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and
Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.
###
Contact
The Investor Relations Group
Erika Moran, Investor Relations
Janet Vasquez, Public Relations
(212) 825-3210
"Reproduced with permission - GeoVax Labs, Inc."
GeoVax Labs, Inc.
|
